Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
DNL-126 by Denali Therapeutics for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ): Likelihood of Approval
DNL-126 is under clinical development by Denali Therapeutics and currently in Phase II for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome...